X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1239) 1239
Publication (101) 101
Book Review (13) 13
Magazine Article (2) 2
Book Chapter (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1026) 1026
male (693) 693
pyridazines - therapeutic use (661) 661
index medicus (637) 637
female (578) 578
pyridazines - adverse effects (481) 481
middle aged (459) 459
adult (365) 365
pyridazines - pharmacology (355) 355
pyridazines - administration & dosage (347) 347
animals (303) 303
aged (272) 272
treatment outcome (269) 269
hydrazones - therapeutic use (265) 265
pharmacology & pharmacy (256) 256
cardiotonic agents - therapeutic use (232) 232
levosimendan (212) 212
heart failure - drug therapy (208) 208
cardiac & cardiovascular systems (205) 205
pyridazines - pharmacokinetics (164) 164
heart failure (159) 159
double-blind method (148) 148
dose-response relationship, drug (144) 144
hiv infections - drug therapy (130) 130
efficacy (129) 129
hemodynamics - drug effects (125) 125
hydrazones - administration & dosage (125) 125
safety (123) 123
time factors (115) 115
drug therapy (111) 111
blood pressure - drug effects (109) 109
hydrazones - pharmacology (106) 106
cardiotonic agents - administration & dosage (105) 105
cardiotonic agents - adverse effects (104) 104
hydrazones - adverse effects (104) 104
dobutamine (103) 103
double-blind (103) 103
drug therapy, combination (100) 100
analysis (99) 99
pharmacokinetics (99) 99
adolescent (98) 98
research (96) 96
cardiotonic agents - pharmacology (94) 94
rats (93) 93
drug interactions (88) 88
heart failure - physiopathology (87) 87
therapy (87) 87
care and treatment (86) 86
calcium sensitizer (85) 85
hypertension, pulmonary - drug therapy (85) 85
vasodilator agents - therapeutic use (84) 84
etravirine (83) 83
clinical trials as topic (82) 82
mortality (82) 82
heart rate - drug effects (78) 78
infectious diseases (77) 77
randomized controlled trials as topic (75) 75
young adult (75) 75
administration, oral (73) 73
infusions, intravenous (73) 73
antihypertensive agents - therapeutic use (71) 71
phenylpropionates - therapeutic use (70) 70
mice (69) 69
medicine & public health (68) 68
health aspects (67) 67
pyridazines - chemistry (67) 67
prospective studies (64) 64
dosage and administration (63) 63
anti-hiv agents - adverse effects (61) 61
hypertension - drug therapy (61) 61
cardiac patients (60) 60
heart-failure (60) 60
drug administration schedule (59) 59
clinical trials (57) 57
hypertension (56) 56
oncology (56) 56
anti-hiv agents - administration & dosage (55) 55
hiv (55) 55
immunology (55) 55
placebo-controlled trial (55) 55
surgery (55) 55
trial (54) 54
hemodynamics (53) 53
imidazoles - adverse effects (53) 53
respiratory system (53) 53
anti-hiv agents - therapeutic use (52) 52
follow-up studies (52) 52
aged, 80 and over (51) 51
pulmonary hypertension (51) 51
tmc125 etravirine (51) 51
cardiovascular (50) 50
acute disease (49) 49
ambrisentan (49) 49
anesthesiology (49) 49
antihypertensive agents - adverse effects (49) 49
medicine, general & internal (49) 49
reverse transcriptase inhibitors - therapeutic use (49) 49
chemistry, medicinal (48) 48
dogs (48) 48
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (48) 48
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1164) 1164
German (23) 23
Spanish (23) 23
French (11) 11
Italian (6) 6
Russian (5) 5
Japanese (4) 4
Chinese (3) 3
Slovak (2) 2
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 612 - 621
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 08/2016, Volume 63, Issue 8, pp. 1332 - 1338
Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with chronic myelogenous leukemia (CML). As children have a much longer... 
growth | CML | TKI | children | endocrine | OSTEOBLAST DIFFERENTIATION | RECEIVING IMATINIB | DASATINIB | MESENCHYMAL STEM-CELLS | CHRONIC MYELOID-LEUKEMIA | GROWTH-HORMONE | ONCOLOGY | BONE-FORMATION | PEDIATRIC-PATIENTS | PEDIATRICS | SOCIETY-DRUG | HEMATOLOGY | IMATINIB MESYLATE | Endocrine System Diseases - chemically induced | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Bone Remodeling - drug effects | Imatinib Mesylate - therapeutic use | Antineoplastic Agents - adverse effects | Imatinib Mesylate - adverse effects | Endocrine System - drug effects | Imidazoles - therapeutic use | Adrenal Glands - drug effects | Child | Pyridazines - adverse effects | Pyridazines - therapeutic use | Thyroid Gland - drug effects | Imidazoles - adverse effects | Dasatinib - therapeutic use | Glucose Metabolism Disorders - chemically induced | Endocrine System - pathology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Dasatinib - adverse effects | Quinolines - therapeutic use | Aniline Compounds - therapeutic use | Aniline Compounds - adverse effects | Nitriles - adverse effects | Quinolines - adverse effects | Nitriles - therapeutic use | Tyrosine | Physiological aspects | Phenols | Chronic myeloid leukemia | Children | Health aspects | Pediatrics | Leukemia
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 19, pp. 1783 - 1796
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 9, pp. 834 - 844
Patients with previously untreated pulmonary arterial hypertension who were randomly assigned to combination therapy with ambrisentan and tadalafil had a... 
INHALED ILOPROST | SURVIVAL | TRIAL | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | EPOPROSTENOL | COMBINATION THERAPY | HEART-FAILURE | DOUBLE-BLIND | BOSENTAN | Hypertension, Pulmonary - mortality | Double-Blind Method | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Hypertension, Pulmonary - physiopathology | Male | Hospitalization | Disease Progression | Tadalafil | Phenylpropionates - therapeutic use | Peptide Fragments - blood | Adult | Female | Phenylpropionates - adverse effects | Aged | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Natriuretic Peptide, Brain - blood | Pyridazines - adverse effects | Pyridazines - therapeutic use | Symptomatology | Care and treatment | Usage | Analysis | Clinical trials | Dosage and administration | Pulmonary hypertension | Ambrisentan | Hypertension | Edema | Brain natriuretic peptide | Headache | Functional morphology | Pulmonary arteries | Lung diseases | Drug therapy | Patients | Clinical outcomes | Drug side effects | Assaigs clínics de medicaments | Efectes secundaris dels medicaments | Hipertensió pulmonar | Drug testing | Life Sciences | Human health and pathology | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
JAMA, ISSN 0098-7484, 08/2017, Volume 318, Issue 6, pp. 548 - 556
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2017, Volume 376, Issue 21, pp. 2021 - 2031
Journal Article
Hepatology, ISSN 0270-9139, 07/2014, Volume 60, Issue 1, pp. 56 - 64
Journal Article
Science, ISSN 0036-8075, 06/2017, Volume 356, Issue 6342, pp. 1084 - 1087
A recent phase 1 trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 led to the death of one volunteer and produced mild-to-severe... 
MOLECULAR CHARACTERIZATION | ENZYME | PAIN | ACID AMIDE HYDROLASE-1 | CLINICAL-TRIAL | MULTIDISCIPLINARY SCIENCES | ANANDAMIDE | RECEPTOR | BLOCKADE | ESTERASE | PF-04457845 | Anti-Anxiety Agents - metabolism | Analgesics - pharmacology | Pyridines - chemistry | Humans | Analgesics - metabolism | Pyridazines - pharmacology | Protein Interaction Maps | Pyridines - adverse effects | Cyclic N-Oxides - adverse effects | Cyclic N-Oxides - pharmacology | Urea - analogs & derivatives | Cyclic N-Oxides - metabolism | Anti-Anxiety Agents - adverse effects | Anti-Anxiety Agents - chemistry | Neurons - metabolism | Neurons - drug effects | Pyridazines - therapeutic use | Analgesics - adverse effects | Anti-Anxiety Agents - pharmacology | Amidohydrolases - antagonists & inhibitors | Cross Reactions | Cyclic N-Oxides - chemistry | Urea - therapeutic use | Pyridines - metabolism | Analgesics - chemistry | Cell Line, Tumor | Pyridines - pharmacology | Clinical Trials, Phase I as Topic | Urea - pharmacology | Amino acid sequence | Methods | Fatty-acid amide hydrolase | Brain | Profiling | Hydrolase | Neurons | Therapeutic applications | Cortex | Nervous system | Tissue analysis | Metabolism | Lipase | Tissues | Fatty acids | Proteins | Neurotoxicity | Pain | Inhibitors | Brain damage | Anxiety | Lipid metabolism | Brain injury | Index Medicus | Drugs | Networks | Proteomics | Amides
Journal Article
Seminars in Oncology, ISSN 0093-7754, 2015, Volume 42, Issue 6, pp. 876 - 886
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 22, pp. 2075 - 2088
Ponatinib was developed to overcome resistance to the tyrosine kinase inhibitors used to treat leukemias that are positive for the Philadelphia chromosome. In... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, GENERAL & INTERNAL | RESPONSE CRITERIA | KINASE DOMAIN MUTATIONS | DIAGNOSED CHRONIC-PHASE | TYROSINE KINASE | INTERNATIONAL-WORKING-GROUP | FOLLOW-UP | CLINICAL RESISTANCE | BCR-ABL INHIBITOR | CHRONIC MYELOID-LEUKEMIA | Amylases - blood | Lipase - blood | Follow-Up Studies | Humans | Middle Aged | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Imidazoles - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Drug Resistance, Neoplasm | Male | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Protein-Tyrosine Kinases - genetics | Antineoplastic Agents - adverse effects | Pyridazines - administration & dosage | Aged, 80 and over | Adult | Female | Pyridazines - adverse effects | Imidazoles - adverse effects | Antineoplastic Agents - chemistry | Pancreatitis - chemically induced | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Patient outcomes | BCR-ABL tyrosine kinase inhibitors | Dosage and administration | Genetic aspects | Acute lymphocytic leukemia | Research | Drug therapy | Tyrosine | BCR protein | Acute lymphatic leukemia | Myeloid leukemia | Leukemia | Pancreatitis | Abl protein | Chronic myeloid leukemia | Lymphatic leukemia | Lipase | Kinases | Philadelphia chromosome | Proteins | Myelosuppression | Fusion protein | Protein-tyrosine kinase | Binding sites | Index Medicus | Abridged Index Medicus
Journal Article